Invasive pulmonary aspergillosis in critically ill patients with COVID-19 in Australia: implications for screening and treatment.
COVID-19
COVID-19-associated pulmonary aspergillosis
acute respiratory distress syndrome
dexamethasone
voriconazole
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
15
10
2021
received:
08
07
2021
accepted:
15
10
2021
entrez:
23
12
2021
pubmed:
24
12
2021
medline:
6
1
2022
Statut:
ppublish
Résumé
We report four cases of invasive pulmonary aspergillus co-infection in patients with coronavirus disease 2019 (COVID-19) infection and acute respiratory distress syndrome requiring intensive care unit (ICU) admission. Aspergillus fumigatus and Aspergillus terreus were isolated, with early infection onset following ICU admission. Clinicians should be aware of invasive pulmonary aspergillosis in ICU patients with COVID-19 infection, particularly those receiving dexamethasone. We propose screening of these high-risk patients with twice-weekly fungal culture from tracheal aspirate and, if feasible, Aspergillus polymerase chain reaction. Diagnosis is challenging and antifungal treatment should be considered in critically ill patients who have new or worsening pulmonary changes on chest imaging and mycological evidence of infection.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2129-2132Subventions
Organisme : Merck
Organisme : F2G
Organisme : Gilead
Organisme : Funding: None.
Informations de copyright
© 2021 Royal Australasian College of Physicians.
Références
Verweij PE, Rijnders BJA, Bruggemann RJM, Azoulay E, Bassetti M, Blot S et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med 2020; 46: 1524-35.
Arastehfar A, Carvalho A, van de Veerdonk FL, Jenks JD, Koehler P, Krause R et al. COVID-19 associated pulmonary aspergillosis (CAPA) - from immunology to treatment. J Fungi (Basel) 2020; 6: 91.
Bartoletti M, Pascale R, Cricca M, Rinaldi M, Maccaro A, Bussini L et al. Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study. Clin Infect Dis 2020; ciaa1065.
White PL, Dhillon R, Cordey A, Hughes H, Faggian F, Soni S et al. A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. Clin Infect Dis 2021; 73: e1634-44.
Koehler P, Cornely OA, Böttiger BW, Dusse F, Eichenauer DA, Fuchs F et al. COVID-19 associated pulmonary aspergillosis. Mycoses 2020; 63: 528-34.
van Arkel ALE, Rijpstra TA, Belderbos HNA, van Wijngaarden P, Verweij PE, Bentvelsen RG. COVID-19-associated pulmonary aspergillosis. Am J Respir Crit Care Med 2020; 202: 132-5.
Alanio A, Dellière S, Fodil S, Bretagne S, Mégarbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med 2020; 8: e48-9.
RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384: 693-704.
Maeda T, Obata R, Rizk D, Kuno T. The association of interleukin-6 value, interleukin inhibitors, and outcomes of patients with COVID-19 in New York City. J Med Virol 2021; 93: 463-71.
Kimmig LM, Wu D, Gold M, Pettit NN, Pitrak D, Mueller J et al. IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. Preprint. Front Med (Lausanne) 2020; 7: 583897-.
Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis 2021; 21: e149-62.
Fekkar A, Neofytos D, Nguyen MH, Clancy CJ, Kontoyiannis DP, Lamoth F. COVID-19-associated pulmonary aspergillosis (CAPA): how big a problem is it? Clin Microbiol Infect 2021; 27: 1376-8.
Lamoth F, Lewis RE, Walsh TJ, Kontoyiannis DP. Navigating the uncertainties of COVID-19 associated aspergillosis (CAPA): a comparison with influenza associated aspergillosis (IAPA). J Infect Dis 2021. https://doi.org/10.1093/infdis/jiab163.
Kula BE, Clancy CJ, Hong Nguyen M, Schwartz IS. Invasive mould disease in fatal COVID-19: a systematic review of autopsies. Lancet Microbe 2021; 2: e405-14.
Jabeen K, Farooqi J, Irfan M, Ali SA, Denning DW. Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis. Lancet Infect Dis 2021; 21: 767.
Permpalung N, Maertens J, Marr KA. Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis. Lancet Infect Dis 2021; 21: 766-7.
Ergün M, Brüggemann RJM, Alanio A, Dellière S, van Arkel A, Bentvelsen RG et al. Aspergillus test profiles and mortality in critically-ill COVID-19 patients. J Clin Microbiol 2021: Jcm0122921.
McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infect Dis 2020; 7: ofaa105.
Maertens JA, Rahav G, Lee DG, Ponce-de-León A, Ramírez Sánchez IC, Klimko N et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet 2021; 397: 499-509.
Mellinghoff SC, Bassetti M, Dörfel D, Hagel S, Lehners N, Plis A et al. Isavuconazole shortens the QTc interval. Mycoses 2018; 61: 256-60.